In recent years, targeted EGFR-TKI therapy has been the first choice for patients with advanced NSCLC and EGFR mutations; although the quality of life of patients has considerably improved with this treatment, drug resistance is inevitable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.